Retatrutide: As of the latest information, retatrutide is still in clinical trials and not yet FDA-approved for any use
Wegovy, Zepbound, and Mounjaro are registered trademarks of their respective owners
The infrastructure is now being built: the CMS-0057-F rule mandates FHIR-based PA APIs by January 2027, AHIP pledges are driving operational improvements since January 2026, and the Medicare GLP-1 Bridge demonstration starting July 2026 will test centralized electronic PA at unprecedented scale
In studies with diet-induced NAFLD mice, GLP-1RAs treatment was effective in improving LFC, which is attributed to a reduction in oxidative stress achieved through a specific cellular pathway involving sirtuin 1 [30,31]
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications approved by the FDA for type 2 diabetes management and, in some formulations, chronic weight management